"It is estimated that 24-30% of the global population has Non-Alcoholic Fatty Liver Disease (NAFLD)1, which equates to 1.8 - 2.3 billion people. Of these, it is estimated that 20%, or up to 468 million people, will also develop non-alcoholic steatohepatitis (NASH), the most severe form of NAFLD where inflammation can cause liver damage and fibrosis. "
This is going to be big. RHT's current tech only used for a fairly rare disease. This new tech will be used on hundreds of millions of people.
I expect a major rerate.
Ann: HepaFat-AI gains US FDA clearance, page-6
Add RHT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.23M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200000 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 1400000 | 1 |
View Market Depth
| Last trade - 16.12pm 19/07/2024 (20 minute delay) ? |
| RHT (ASX) Chart |
Day chart unavailable